+2,584.6%
AXTI vs GSK
+47.2%
+2,537.5%
-78.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.1% | -1.0% | -5.1% | -6.1% |
| 7D | +15.1% | -5.4% | +20.5% | +15.1% |
| 30D | -12.3% | -4.6% | -7.7% | -12.4% |
| 3M | -24.1% | -5.1% | -19.0% | -24.4% |
| 6M | +46.0% | -11.4% | +57.5% | +47.7% |
| YTD | +295.7% | +0.7% | +295.0% | +290.3% |
| 1Y | +1,825.6% | +23.0% | +1,802.6% | +1,723.8% |
| All | +2,584.6% | +47.2% | +2,537.5% | +2,436.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling